In 2010, Biogen Idec licensed dexpramipexole (Dex) from Knopp Biosciences for $80 million to further develop the drug candidate for the treatment of ALS. After promising Phase II results, Biogen launched a global Phase III study of Dex in over 900 people with ALS. Although the Phase III trial is still ongoing, Knopp has started to raise funds to support studies that would test Dex for the treatment of other neurodegenerative diseases. Knopp’s goal is to raise $30 million, and they are about halfway there. Hopefully these additional studies will provide further insights into the results of the soon-to-be-announced Dex ALS study!
Click here to read more.Share this: